导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.29% | 217/4773 |
| 近一周 | -2.16% | 1353/5462 |
| 近一月 | -7.81% | 3995/5421 |
| 近一季 | -12.10% | 3806/5209 |
| 近半年 | 19.48% | 178/4920 |
| 近一年 | 26.84% | 253/4366 |
| 近两年 | 148.36% | 207/2954 |
| 近三年 | 116.36% | 75/2253 |
| 成立以来 | 100.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.10% 4030/4961 |
81.68% 173/5312 |
- - |
- - |
| 2025 | 43.96% 645/4813 |
1.94% 1509/3635 |
-0.32% 2887/4076 |
50.76% 292/4524 |
-6.03% 3661/4813 |
| 2024 | 22.51% 379/3463 |
-5.26% 1859/2808 |
2.46% 350/3014 |
13.51% 2159/3129 |
11.18% 231/3463 |
| 2023 | 5.50% 188/2656 |
18.51% 160/2280 |
-3.11% 741/2385 |
-8.08% 1660/2515 |
-0.05% 175/2655 |
| 2022 | -35.89% 1734/2207 |
-23.81% 1744/1919 |
0.41% 1551/2016 |
-18.08% 1678/2113 |
2.30% 985/2208 |
| 2021 | 10.05% 445/1822 |
-8.27% 1080/1255 |
20.29% 151/1330 |
-8.52% 1135/1466 |
9.03% 130/1822 |
| 2020 | 39.94% 321/1250 |
-1.02% 199/1028 |
27.95% 120/1067 |
3.44% 982/1164 |
6.82% 742/1184 |
| 2019 | 68.04% 32/1092 |
40.89% 44/739 |
-11.95% 778/788 |
21.28% 5/850 |
11.68% 50/918 |
| 2018 | -37.44% 598/834 |
- - |
-14.92% 504/631 |
-12.35% 610/660 |
-15.80% 623/682 |
| 2017 | 19.55% 192/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.38% 416/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证电子ETF联接A VS. 长安沪深300非周期A(740101) |